Your browser doesn't support javascript.
loading
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon, Magnus T; Guevara, Jeane; Mohammed, Kabir; Patin, Emmanuel C; Smith, Simon A; Dean, Emma; Jones, Gemma N; Willis, Sophie E; Petrone, Marcella; Silva, Carlos; Thway, Khin; Bunce, Catey; Roxanis, Ioannis; Nenclares, Pablo; Wilkins, Anna; McLaughlin, Martin; Jayme-Laiche, Adoracion; Benafif, Sarah; Nintos, Georgios; Kwatra, Vineet; Grove, Lorna; Mansfield, David; Proszek, Paula; Martin, Philip; Moore, Luiza; Swales, Karen E; Banerji, Udai; Saunders, Mark P; Spicer, James; Forster, Martin D; Harrington, Kevin J.
Afiliação
  • Dillon MT; The Institute of Cancer Research, London, United Kingdom.
  • Guevara J; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Mohammed K; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Patin EC; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Smith SA; The Institute of Cancer Research, London, United Kingdom.
  • Dean E; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jones GN; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Willis SE; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Petrone M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Silva C; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Thway K; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Bunce C; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Roxanis I; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Nenclares P; The Institute of Cancer Research, London, United Kingdom.
  • Wilkins A; The Institute of Cancer Research, London, United Kingdom.
  • McLaughlin M; The Institute of Cancer Research, London, United Kingdom.
  • Jayme-Laiche A; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Benafif S; The Institute of Cancer Research, London, United Kingdom.
  • Nintos G; UCL Cancer Institute and University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Kwatra V; UCL Cancer Institute and University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Grove L; King's College London, and Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Mansfield D; King's College London, and Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Proszek P; The Institute of Cancer Research, London, United Kingdom.
  • Martin P; The Institute of Cancer Research, London, United Kingdom.
  • Moore L; The Institute of Cancer Research, London, United Kingdom.
  • Swales KE; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Banerji U; Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Saunders MP; Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Spicer J; The Institute of Cancer Research, London, United Kingdom.
  • Forster MD; The Institute of Cancer Research, London, United Kingdom.
  • Harrington KJ; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
J Clin Invest ; 134(2)2024 Jan 16.
Article em En | MEDLINE | ID: mdl-37934611
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Morfolinas / Neoplasias Limite: Humans Idioma: En Revista: J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Morfolinas / Neoplasias Limite: Humans Idioma: En Revista: J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido